CompletedNCT03201757
Long-Term ALKS 3831 Safety in Schizophrenia or Bipolarity
About this title
Read the official source — NCT03201757Medication studyAges 16–70Multiple countries
Understand this study
Who was this study for?
Listed age limits: 16 years to 70 years.
- Listed locations
- Little Rock and 84 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: June 15, 2017
- Recruitment status
- Completed
- Enrollment listed in the registry
- 523
- Sponsor
- Alkermes, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, United Kingdom, Austria, ...
- Age range
- From 16 Years to 70 Years
- Official registry ID
- NCT03201757
- Official title
Show the full official title
A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Little Rock, United States · Rogers, United States · Anaheim, United States
77 more locations
- Cerritos, United States
- Culver City, United States
- Garden Grove, United States
- Glendale, United States
- Long Beach, United States
- Oakland, United States
- Oceanside, United States
- Orange, United States
- Palo Alto, United States
- Pico Rivera, United States
- Redlands, United States
- San Diego, United States
- Temecula, United States
- Torrance, United States
- Lauderhill, United States
- North Miami, United States
- Atlanta, United States
- Augusta, United States
- Decatur, United States
- Chicago, United States
- Winfield, United States
- Grand Rapids, United States
- Flowood, United States
- Kansas City, United States
- St Louis, United States
- Las Vegas, United States
- Berlin, United States
- Marlton, United States
- Brooklyn, United States
- Rochester, United States
- Canton, United States
- Cincinnati, United States
- Dayton, United States
- Eugene, United States
- Austin, United States
- DeSoto, United States
- Fort Worth, United States
- Houston, United States
- Richardson, United States
- Bellevue, United States
- Vienna, Austria
- Burgas, Bulgaria
- Lovech, Bulgaria
- Novi Iskar, Bulgaria
- Plovdiv, Bulgaria
- Sofia, Bulgaria
- Tserova Koria, Bulgaria
- Veliko Tarnovo, Bulgaria
- Vratsa, Bulgaria
- Galway, Ireland
- Jerusalem, Israel
- Ramat Gan, Israel
- Brescia, Italy
- Naples, Italy
- Poznan, Poland
- San Juan, Puerto Rico
- Arkhangelsk, Russia
- Moscow, Russia
- Roshchino, Russia
- Rostov-on-Don, Russia
- Saint Petersburg, Russia
- Samara, Russia
- Saratov, Russia
- Tonnel'nyy, Russia
- Belgrade, Serbia
- Kragujevac, Serbia
- Novi Kneževac, Serbia
- Busan, South Korea
- Kharkiv, Ukraine
- Kherson, Ukraine
- Kyiv, Ukraine
- Lviv, Ukraine
- Poltava, Ukraine
- Smila, Ukraine
- Vinnytsia, Ukraine
- Headington, United Kingdom
- Russia
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Alkermes, Inc.
Did this study involve medication?
Yes. The study involved medication, including ALKS 3831.
Who was this study for?
Listed age limits: 16 years to 70 years.
